Výsledky vyhledávání - "Helen Barnacle"

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

Autor: David A. Lomas, Nicholas Locantore, Steven Pascoe, Andrea Ludwig-Sengpiel, Noushin Brealey, David A. Lipson, Ruby Birk, Chang-Qing Zhu, Helen Barnacle, Maggie Tabberer, Rajat Mohindra

Publikováno v: American Journal of Respiratory and Critical Care Medicine. 196:438-446

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.Objectives: We compared the effects of once-da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d5adf5cd9b77e7dc2ab9eea9589dbc5
https://doi.org/10.1164/rccm.201703-0449oc

Zobrazit plný text záznamu

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

Autor: Mark T. Dransfield, Rajat Mohindra, Ian D. Pavord, Steven Pascoe, Noushin Brealey, Helen Barnacle, David A. Lipson, Nicholas Locantore, Neil Barnes

Publikováno v: European Respiratory Journal. 48:320-330

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a544fed3bb0187561c14401389f1f5
https://doi.org/10.1183/13993003.02165-2015

Zobrazit plný text záznamu

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD

Autor: Misba Beerahee, Chang-Qing Zhu, David A. Lipson, Noushin Brealey, Ruby Birk, Eleni Pefani, Rashmi Mehta, Helen Barnacle

Publikováno v: Journal of Clinical Pharmacology

A population pharmacokinetic analysis was conducted from a subset of samples obtained from the Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy trial to characterize the pharmacokinetics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3c47c0bb6d7a5b0a91ac15f82dc0c55
https://pubmed.ncbi.nlm.nih.gov/29762864

Zobrazit plný text záznamu

Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study

Autor: Noushin Brealey, Ian Naya, Ruby Birk, David A. Lipson, Chang-Qing Zhu, Maggie Tabberer, Helen Barnacle

Publikováno v: Airway Pharmacology and Treatment.

A prospective analysis of clinically important deterioration (CID), a composite measure (lung function, health status and exacerbations) of worsening COPD (Singh, et al. Int J COPD 2016; 11:1413), in the FULFIL study is reported. FULFIL assessed once

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbd0920145b9253e3e2684fcffe2e429
https://doi.org/10.1183/1393003.congress-2017.pa3248

Zobrazit plný text záznamu

Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses

Autor: Helen Barnacle, Mark T. Dransfield, Ruby Birk, David A. Lomas, Noushin Brealey, Chang-Qing Zhu, David A. Lipson

Publikováno v: Airway Pharmacology and Treatment.

Analysis of the FULFIL study by prior medication and disease severity is reported. FULFIL studied single inhaler, once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100μg/62.5μg/25μg vs twice-daily budesonide/formoterol (BUD/FOR)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f43b2400f9a85f14774866b8952c24d
https://doi.org/10.1183/1393003.congress-2017.pa1057

Zobrazit plný text záznamu

Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)

Autor: Helen Barnacle, Ruby Birk, Rashmi Mehta, Misba Beerahee, Chang-Qing Zhu, Eleni Pefani, David A. Lipson, Noushin Brealey

Publikováno v: Airway Pharmacology and Treatment.

Background: FULFIL showed statistically significant improvements in trough FEV 1 and health status with once-daily FF/UMEC/VI 100μg/62.5μg/25μg via the ELLIPTA ® inhaler (n=911) vs twice-daily budesonide/formoterol (BUD/FOR) 400μg/12μg via the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dde5ec6f57305618c39f65162cc5647f
https://doi.org/10.1183/1393003.congress-2017.pa3252

Zobrazit plný text záznamu

Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes

Autor: Helen Barnacle, Ruby Birk, Chang-Qing Zhu, David M.G. Halpin, Noushin Brealey, Mark T. Dransfield, David A. Lipson

Publikováno v: Airway Pharmacology and Treatment.

Background: FULFIL reported statistically significant improvements in lung function and health status with once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100μg/62.5μg/25μg via the ELLIPTA® inhaler vs twice-daily budesonide/fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60ecbfc198267cf00947402a36259eb8
https://doi.org/10.1183/1393003.congress-2017.pa1069

Zobrazit plný text záznamu

Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial

Autor: Helen Barnacle, Benjamin Hartley, Robert Chan, Henrik Watz

Publikováno v: The Lancet Respiratory Medicine. 2:63-72

The p38 MAPK pathway seems to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD). Losmapimod is a potent and selective inhibitor of p38 MAPK. We assessed the effect of losmapimod on exercise tolerance in patients with COPD.We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ead4db17273bdba163d089c3672a75
https://doi.org/10.1016/s2213-2600(13)70200-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání